Methylation of arsenic by recombinant human wild-type arsenic (+3 oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorph: Role of glutathione

Toxicology and Applied Pharmacology

Volumn 264, Issue 1, 2012, Pages 121-130

  Ding, Lan ^a   Saunders, R Jesse ^a   Drobná, Zuzana ^a   Walton, Felecia S ^a   Xun, Pencheng ^a   Thomas, David J ^b   Stýblo, Miroslav ^a  

^a University of North Carolina   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Arsenic methylation; AS3MT polymorphism; Glutathione; Thioredoxin reductase

Indexed keywords

ARSENIC; ARSENIC METHYLTRANSFERASE; ARSENIC TRIOXIDE; CACODYLIC ACID; GLUTATHIONE; METHANEARSONIC ACID; METHIONINE; S ADENOSYLMETHIONINE; THIOREDOXIN REDUCTASE; THREONINE; UNCLASSIFIED DRUG;

ARSENIC METHYLATION; ARTICLE; AS3MT GENE; CATALYSIS; DISEASE PREDISPOSITION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; METHYLATION; MICHAELIS MENTEN KINETICS; OXIDATION; PHENOTYPE;

ANIMALS; ARSENICALS; ARSENITES; GLUTATHIONE; HUMANS; METHYLATION; METHYLTRANSFERASES; PHOSPHINES; POLYMORPHISM, GENETIC; RATS; S-ADENOSYLMETHIONINE; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84865980440     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.07.024     Document Type: Article

References (43)

1. Agusa T., Iwata H., Fujihara J., Kunito T., Takeshita H., Minh T.B., Trang P.T., Viet P.H., Tanabe S. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol. 2009, 236:131-141.
2. Challenger F. Biological methylation. Adv. Enzymol. 1951, 12:429-491.
3. Chen B., Arnold L.L., Cohen S.M., Thomas D.J., Le X.C. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol. Sci. 2011, 124:320-326.
4. Chung C.J., Hsueh Y.M., Bai C.H., Huang Y.K., Huang Y.L., Yang M.H., Chen C.J. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Control 2009, 20:1653-1661.
5. Cullen W.R., McBride B.C., Reglinski J. The reduction of trimethylarsine oxide to trimethylarsine by thiols: a mechanistic model for the biological reduction of arsenicals. J. Inorg. Biochem. 1984, 21:45-60.
6. Del Razo L.M., Styblo M., Cullen W.R., Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 2001, 174:282-293.
7. Del Razo L.M., García-Vargas G.G., Valenzuela O.L., Hernandez-Castellanos E., Sánchez-Peña L.C., Drobná Z., Loomis D., Stýblo M. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapán and Lagunera Regions in Mexico. Environ. Health 2011, 10:73.
8. Devesa V., Del Razo L.M., Adair B., Drobná Z., Waters S.B., Hughes M.F., Styblo M., Thomas D.J. Comprehensive analysis of arsenic metabolites by pH-specific hydride generation atomic absorption spectrometry. J. Anal. At. Spectrom. 2004, 19:1460-1467.
9. Drobná, Z., Del Razo, L.M., García-Vargas, G.G., Valenzuela, O.L., Hernandez-Castellanos, E., Sánchez-Peña, L.C., Stýblo, M., Loomis, D., in press. AS3MT polymorphism and prevalence of diabetes among residents of the Zimapan and Lagunera regions in Mexico. J. Expo. Sci. Environ. Epidemiol.
10. Engström K.S., Broberg K., Concha G., Nermell B., Warholm M., Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect. 2007, 115:599-605.
11. Engström K., Vahter M., Mlakar S.J., Concha G., Nermell B., Raqib R., Cardozo A., Broberg K. Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 2011, 119:182-188.
12. Fujihara J., Fujii Y., Agusa T., Kunito T., Yasuda T., Moritani T., Takeshita H. Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol. Appl. Pharmacol. 2009, 234:41-46.
13. Gallogly M.M., Mieyal J.J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol. 2007, 7:381-391.
14. Hayakawa T., Kobayashi Y., Cui X., Hirano S. A new metabolic pathway of arsenite: arsenite-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol. 2005, 79:183-191.
15. Hernández A., Marcos R. Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics 2008, 9:1113-1132.
16. Hernández A., Xamena N., Sekaran C., Tokunaga H., Sampayo-Reyes A., Quinteros D., Creus A., Marcos R. High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet. Genomics 2008, 18:349-355.
17. Hernández A., Xamena N., Surrallés J., Sekaran C., Tokunaga H., Quinteros D., Creus A., Marcos R. Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat. Res. 2008, 637:80-92.
18. Hernández-Zavala A., Matoušek T., Drobná Z., Adair B.M., Dědina J., Thomas D.J., Stýblo M. Speciation of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J. Anal. At. Spectrom. 2008, 23:342-351.
19. Hsieh Y.C., Lien L.M., Chung W.T., Hsieh F.I., Hsieh P.F., Wu M.M., Tseng H.P., Chiou H.Y., Chen C.J. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ. Res. 2011, 111:804-810.
20. Hughes M.F., Edwards B.C., Herbin-Davis K.M., Saunders J., Styblo M., Thomas D.J. Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice. Toxicol. Appl. Pharmacol. 2010, 249:217-223.
21. Hwang Y.H., Chen Y.H., Su Y.N., Hsu C.C., Chen Y.H., Yuan T.H. Genetic polymorphism of As3MT and delayed urinary DMA excretion after organic arsenic intake from oyster ingestion. J. Environ. Monit. 2010, 12:1247-1254.
22. Lin S., Cullen W.R., Thomas D.J. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol. 1999, 12:924-930.
23. Lin S., Del Razo L.M., Styblo M., Wang C., Cullen W.R., Thomas D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol. 2001, 14:305-311.
24. Lin S., Shi Q., Nix F.B., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., Thomas D.J. A novel S-adenosyl-L-methionine: arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 2002, 277:10795-10803.
25. Lindberg A.L., Kumar R., Goessler W., Thirumaran R., Gurzau E., Koppova K., Rudnai P., Leonardi G., Fletcher T., Vahter M. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect. 2007, 115:1081-1086.
26. Marapakala K., Qin J., Rosen B.P. Identification of catalytic residues in the As(III) S-adenosylmethionine methyltransferase. Biochemistry 2012, 51:944-951.
27. Matoušek T., Hernández-Zavala A., Svoboda M., Langerová L., Adair B.M., Drobná Z., Thomas D.J., Stýblo M., Dědina J. Oxidation state specific generation of arsines from methylated arsenicals based on L-cysteine treatment in buffered media for speciation analysis by hydride generation-automated cryotrapping-gas chromatography-atomic absorption spectrometry with the multiatomizer. Spetrochim. Acta Part B 2008, 63:396-406.
28. Messens J., Silver S. Arsenate reduction: thiol cascade chemistry with convergent evolution. J. Mol. Biol. 2006, 362:1-17.
29. Pierce B.L., Kibriya M.G., Tong L., Jasmine F., Argos M., Roy S., Paul-Brutus R., Rahaman R., Rakibuz-Zaman M., Parvez F., Ahmed A., Quasem I., Hore S.K., Alam S., Islam T., Slavkovich V., Gamble M.V., Yunus M., Rahman M., Baron J.A., Graziano J.H., Ahsan H. Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet. 2012, 82:e1002522.
30. Roos G., Foloppe N., Van Laer K., Wyns L., Nilsson L., Geerlings P., Messens J. How thioredoxin dissociates its mixed disulfide. PLoS Comput. Biol. 2009, 5(8):e1000461.
31. Sampayo-Reyes A., Hernández A., El-Yamani N., López-Campos C., Mayet-Machado E., Rincón-Castañeda C.B., Limones-Aguilar Mde L., López-Campos J.E., de León M.B., González-Hernández S., Hinojosa-Garza D., Marcos R. Arsenic induces DNA damage in environmentally exposed Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. Toxicol. Sci. 2010, 117:63-71.
32. Song X., Geng Z., Zhu J., Li C., Hu X., Bian N., Zhang X., Wang Z. Structure-function roles of four cysteine residues in the human arsenic (+3 oxidation state) methyltransferase (hAS3MT) by site-directed mutagenesis. Chem. Biol. Interact. 2009, 179:321-328.
33. Song X., Geng Z., Li X., Hu X., Bian N., Zhang X., Wang Z. New insights into the mechanism of arsenite methylation with the recombinant human arsenic (+3) methyltransferase (hAS3MT). Biochimie 2010, 92:1397-1406.
34. Styblo M., Delnomdedieu M., Thomas D.J. Biological mechanisms and toxicological consequences of the methylation of arsenic. Handbook of Experimental Pharmacology 1995, vol. 115:407-433. Springer Verlag, Berlin. M.G. Cherian, R.A. Goyer (Eds.).
35. Sun Q.A., Wu Y., Zappacosta F., Jeang K.T., Lee B.J., Hatfield D.L., Gladyshev V.N. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J. Biol. Chem. 1999, 274:24522-24530.
36. Thomas D.J., Styblo M., Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 2001, 176:127-144.
37. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., Styblo M. Arsenic (+3 oxidation state) methyltransferase and methylation of arsenicals. Exp. Biol. Med. 2007, 232:3-13.
38. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. Sci. Prog. 1999, 82:69-88.
39. Valenzuela O.L., Borja-Aburto V.H., Garcia-Vargas G.G., Cruz M.B., Calderon-Aranda E.M., Del Razo L.M. Urinary trivalent methylated arsenic species in population chronically exposed to inorganic arsenic. Environ. Health Perspect. 2005, 113:250-254.
40. Valenzuela O.L., Drobná Z., Hernández-Castellanos E., Sánchez-Peña L.C., García-Vargas G.G., Borja-Aburto V.H., Stýblo M., Del Razo L.M. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol. Appl. Pharmacol. 2009, 239:200-207.
41. Waters S.B., Devesa-Perez V., Del Razo L.M., Styblo M., Thomas D.J. Endogenous reductants support catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem. Res. Toxicol. 2004, 17:404-409.
42. Waters S.B., Devesa V., Fricke M.W., Creed J.T., Styblo M., Thomas D.J. Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem. Res. Toxicol. 2004, 17:1621-1629.
43. Wood T.C., Salavagionne O.E., Mukherjee B., Wang L., Klumpp A.F., Thomae B.A., Eckloff B.W., Schaid D.J., Wieben E.D., Weinshilboum R.M. Human arsenic methyltransferase (AS3MT) pharmacogenetics. Gene resequencing and functional genomics studies. J. Biol. Chem. 2006, 281:7364-7373.